{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.74","upperLimit":"6.47","value":"5.08"},{"groupId":"OG001","lowerLimit":"0.72","upperLimit":"16.26","value":"6.95"},{"groupId":"OG002","lowerLimit":"2.50","upperLimit":"29.80","value":"7.89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"OS was defined as the time from the first dose date to the date of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pediatric participants with RMS received eribulin mesylate as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m\\^2. Participants continued to receive study therapy until progression of disease, (per RECIST 1.1), exhibited no clinical benefit, intolerable toxicity, withdrawal of consent or termination of the study program, whichever occurred first.","id":"OG000","title":"Eribulin Mesylate 1.4 mg/m^2: RMS"},{"description":"Pediatric participants with non-rhabdomyosarcoma solid tumor sarcoma (NRSTS) received eribulin mesylate as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m\\^2. Participants continued to receive study therapy until progression of disease, (per RECIST 1.1), exhibited no clinical benefit, intolerable toxicity, withdrawal of consent or termination of the study program, whichever occurred first.","id":"OG001","title":"Eribulin Mesylate 1.4 mg/m^2: NRSTS"},{"description":"Pediatric participants with EWS received eribulin mesylate as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m\\^2. Participants continued to receive study therapy until progression of disease, (per RECIST 1.1), exhibited no clinical benefit, intolerable toxicity, withdrawal of consent or termination of the study program, whichever occurred first.","id":"OG002","title":"Eribulin Mesylate 1.4 mg/m^2: EWS"}],"paramType":"MEDIAN","populationDescription":"The FAS included all participants who receive at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From the day of first dose to the day of death, up to approximately 45 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}